HOME >> BIOLOGY >> NEWS
Clinical trial will test controlled 'drug holidays' to counter HIV

Researchers have received approval for a new clinical trial to test carefully controlled interruptions in HIV patients' drug regimens as an approach to boosting their immune systems, eventually to the point where they can manage their infections without the need for drugs. Patient recruitment will begin immediately for the trial, which was conceived by a team of scientists headed by Luis J. Montaner, D.V.M., D.Phil., an assistant professor at The Wistar Institute, and will be overseen by clinicians in the University of Pennsylvania Health System.

Current state-of-the-art therapy for HIV infection is to administer a cocktail of three drugs that suppresses the virus, often to undetectable levels. While the treatment, known as Highly Active Anti-Retroviral Therapy, or HAART, is very effective, it is too expensive to represent a worldwide solution to the problem of HIV and AIDS. It is also complex and burdensome for patients to adhere to, and it is often accompanied by disturbing, potentially dangerous side effects. While patients are under therapy, however, the number of viruses in their blood drops, and the immune system recovers its ability to respond.

Researchers at The Wistar Institute and elsewhere believe that carefully structured "holidays" from the drugs - known as intermittent HAART - might lead, in effect, to autovaccination against HIV. Patients' ability to mount a response to their own virus has been observed by Dr. Montaner and his colleagues in a subset of chronically infected patients who had maintained long-term viral suppression with their medications before a controlled interruption of treatment. The present trial will test the capacity of these responses to control HIV without medication.

"Many people feel that the answer to AIDS will be found in improved antiviral drugs," says Dr. Montaner, principal investigator on the scientific study that led to development of the new trial. "Immunologists like myself, however, see in the drugs an
'"/>

Contact: Franklin Hoke
hoke@wistar.upenn.edu
215-898-3716
The Wistar Institute
15-May-2000


Page: 1 2

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical trial shows timing of chemotherapy improves survival in breast cancer
11. Clinical services must catch up

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
Breaking Biology News(10 mins):
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... Algenist continues ... collagen-based formulation unlocking collagen like never before. , Collagen is the key structural ... to market with Liquid Collagen™, which include: , First ...
(Date:8/10/2017)... NC (PRWEB) , ... August 09, 2017 , ... Each ... Almost half never recover well enough to live an independent lifestyle and, even worse, ... , A new discovery by doctors at the University of California Davis Medical Center ...
(Date:8/10/2017)... ... August 10, 2017 , ... CNA ... outlet had initiated coverage on Next Group Holdings, Inc. and see's significant opportunity ... geared toward those that cannot engage in traditional banking services. According to industry ...
(Date:8/8/2017)... ... August 08, 2017 , ... Cynvenio Biosystems, Inc. ... announced the launch of its second generation PD-L1 expression test. The new blood ... highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer ...
Breaking Biology Technology:
Cached News: